Close Menu

This article has been updated from a previous version to include a statement provided by Epigenomics.

NEW YORK (GenomeWeb) – BioChain said today that it is considering legal action against Epigenomics for allegedly violating the terms of a licensing contract related to Chinese distribution rights to Epigenomics' Septin9 biomarker and Epi proColon colorectal cancer blood test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.